You are here

Novartis

ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

Fierce Pharma

non-small cell lung cancer

early breast cancer

Flag link:

Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf

Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf

Fierce Biotech

Flag link:

Novartis brings on 8 business vets for Sandoz's new board, including 4 women

Novartis brings on 8 business vets for Sandoz's new board, including 4 women

Fierce Pharma

women executives

Flag link:

The waxing and waning of the speedy approval

The waxing and waning of the speedy approval

EP Vantage

accelerated approvals

Bristol Myers Squibb

Flag link:

Sandoz taps Evotec in long-term biosimilar development and manufacturing deal

Sandoz taps Evotec in long-term biosimilar development and manufacturing deal

Fierce Pharma

Flag link:

A blockbuster year could be building

A blockbuster year could be building

EP Vantage

Bristol Myers Squibb

Gilead Sciences

Horizon Therapeutics

Moderna Therapeutics

Flag link:

Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations

Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations

BioSpace

Flag link:

Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold

Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold

Fierce Pharma

Flag link:

'More in the hopper': European Big Pharmas hint M&A could ramp up

'More in the hopper': European Big Pharmas hint M&A could ramp up

Fierce Biotech

Flag link:

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Clinical Trials Arena

clinical trials

Flag link:

Bristol Myers boosts cell therapy production with Novartis plant

Bristol Myers boosts cell therapy production with Novartis plant

BioPharma Dive

Bristol Myers Squibb

drug manufacturing

Flag link:

Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

BioSpace

cardiovascular disease

Flag link:

Point looks to turn the tables on Novartis

Point looks to turn the tables on Novartis

EP Vantage

Point Biopharma

radiopharmaceuticals

Flag link:

Novartis, helped by cost cuts, raises full-year outlook

Novartis, helped by cost cuts, raises full-year outlook

Reuters

Flag link:

Novartis strikes $425M deal with 3BP for FAP-targeting peptide technology

Novartis strikes $425M deal with 3BP for FAP-targeting peptide technology

Medical Marketing and Media

3B Pharmaceuticals

FAP-targeting peptides

Flag link:

Novartis plant cleared to produce in-demand cancer drug

Novartis plant cleared to produce in-demand cancer drug

BioPharma Dive

drug manufacturing

radiopharmaceuticals

Flag link:

FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market

FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market

Fierce Biotech

Flag link:

Big pharma’s biggest spenders revealed: 2022 edition

Big pharma’s biggest spenders revealed: 2022 edition

EP Vantage

Bristol Myers Squibb

Flag link:

AACR 2023 – Hippo makes a splash

AACR 2023 – Hippo makes a splash

EP Vantage

Vivace Therapeutics

Flag link:

Pages